tirzepatide hfpef trial In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but offered no additional benefit over semaglutide. #ESCCongress tirzepatide cardiovascular outcomes trial results
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12


























